These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 769971)

  • 1. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
    Johnson RO; Metter G; Wilson W; Hill G; Krementz E
    Cancer Treat Rep; 1976 Feb; 60(2):183-7. PubMed ID: 769971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DTIC (NSC-45388) studies in the southwest oncology group.
    Costanzi JJ
    Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
    Carbone PP; Costello W
    Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DTIC (NSC-45388) in malignant melanoma: a perspective.
    Comis RL
    Cancer Treat Rep; 1976 Feb; 60(2):165-76. PubMed ID: 769969
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
    Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies with DTIC (NSC-45388) in various malignancies.
    Slavik M
    Cancer Treat Rep; 1976 Feb; 60(2):213-4. PubMed ID: 769976
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polychemotherapy with 5-(3,3 dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC; NSC-45388), 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC-409962) and vincristine (NSC-67574) in the metastatic phase of melanoma].
    Beretta G; Bajetta E; Bonadonna G; Tancini G; Orefice S; Veronesi U
    Tumori; 1973; 59(3):239-48. PubMed ID: 4729646
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
    Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
    Chauvergne J; Clavel B; Klein T; Pommatau E
    Bull Cancer; 1978; 65(2):107-9. PubMed ID: 359067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
    Gottlieb JA; Benjamin RS; Baker LH; O'Bryan RM; Sinkovics JG; Hoogstraten B; Quagliana JM; Rivkin SE; Bodey GP; Rodriguez V; Blumenschein GR; Saiki JH; Coltman C; Burgess MA; Sullivan P; Thigpen T; Bottomley R; Balcerzak S; Moon TE
    Cancer Treat Rep; 1976 Feb; 60(2):199-203. PubMed ID: 769974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of therapy on the antioxidant status in patients with melanoma.
    Gadjeva V; Dimov A; Georgieva N
    J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
    Everall JD; Dowd PM
    Cancer Treat Rep; 1979 Jan; 63(1):151-5. PubMed ID: 84710
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma.
    Samson MK; Baker LH; Izbicki RM; Ratanatharathorn V
    Cancer Treat Rep; 1976 Sep; 60(9):1369-71. PubMed ID: 65223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of metastatic malignant melanoma (author's transl)].
    Kühböck J; Pehamberger H; Mach K; Diem E; Kokoschka EM; Pötzi P
    Wien Klin Wochenschr; 1978 Dec; 90(24):856-8. PubMed ID: 84441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.